Autres langues Sirnaomics Ltd.

Actions

2257

KYG2050P1028

Marché Fermé - Hong Kong S.E. Autres places de cotation 10:08:20 14/05/2024			Varia. 5j.	Varia. 1 janv.
7,65 ^HKD	+5,37%		+3,24%	-78,63%

10/05	Sirnaomics Ltd. nomme Edward Yongxiang Wang directeur exécutif	CI
16/04	Sirnaomics Ltd. reçoit des directives spécifiques de la FDA pour la poursuite du développement du nouveau siRNA thérapeutique, STP705, pour le traitement du carcinome épidermoïde in situ	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Sirnaomics Ltd. Appoints Edward Yongxiang Wang as Executive Director	10/05
Sirnaomics Receives US FDA Guidance on Trials for Squamous Cell Carcinoma Treatment	17/04
Sirnaomics Ltd. Receives FDA Specific Guidance for Further Development of novel siRNA therapeutic, STP705 for Treatment of Squamous Cell Carcinoma in situ	16/04
Sirnaomics Announces 2023 Annual Results	28/03
Sirnaomics Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	27/03
Sirnaomics will Present its Innovative Dual-Targeted GalNAc muRNA Programs in 2024 OPT Conference	12/03
Sirnaomics Chairman Disposes of Shares	08/03
Sirnaomics to Present Latest Developments of STP705 for Focal Fat Reduction at IMCAS World Congress 2024	05/02
Sirnaomics Publishes Novel Mechanism of Action of RNAi Cancer Therapeutic STP707 for Solid Tumors	24/01
Basal Cell Carcinoma Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023 (Updated)	20/12
RNAimmune Receives Investigational New Drug Application Clearance from U.S. FDA for mRNA-Based Respiratory Syncytial Virus Vaccine RV-1770	18/12
Sirnaomics Gets US FDA Nod for Clinical Trial of RSV Drug	18/12
Sirnaomics Concludes First Cohort of Phase 1 Anticoagulant Drug Study	06/12
Sirnaomics Announces Successful Completion of Cohort 1 from Phase I Clinical Study of GalNAc-Based RNAi Therapeutic STP122G for Anticoagulant Treatment	05/12
Sirnaomics Ltd. Announces Successful Completion of Cohort 1 from Phase I Clinical Study of GalNAc-Based RNAi Therapeutic STP122G for Anticoagulant Treatment	05/12
Sirnaomics Promotes Francois Lebel, M.D. to Chief Medical Officer	04/12
Sirnaomics Promotes Francois Lebel, M.D. to Chief Medical Officer	01/12
Sirnaomics Ltd. Announces Executive Changes	30/11
Sirnaomics Shows Positive Effects of Focal Fat Reduction Drug at US Conference	02/11
Sirnaomics Presents Positive Clinical Data of STP705 for Focal Fat Reduction	01/11

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Sirnaomics Ltd.

Actions

2257

KYG2050P1028

Autres langues

Filtres